Can Wegovy help you stop smoking — and should that change your decision?

Why researchers started asking whether GLP-1 medicines affect smoking at all

The question first surfaced from an unexpected direction. When patients taking semaglutide or other GLP-1 receptor agonists began reporting reduced interest in alcohol, gambling and cigarettes alongside reduced appetite, researchers took notice. The working hypothesis is that GLP-1 receptors exist not just in the gut and pancreas but also in reward-processing areas of the brain, including the nucleus accumbens. Dopamine-driven reward signals (the same circuits that reinforce nicotine dependence) may be dampened when those receptors are activated.

Observational studies and retrospective analyses have since found that people prescribed semaglutide showed modestly lower rates of ongoing tobacco use in some datasets. A question our prescribers hear most weeks is some version of: "I read that Ozempic stops cravings (does that mean Wegovy will help me quit?" The honest clinical reply is: possibly, in some people, to some degree) but we do not yet know how much, for whom, or whether it is enough to matter on its own. Observational data cannot establish cause and effect, and the populations in those studies were not selected or monitored for smoking outcomes. The full picture of how Wegovy works in the body is still being mapped.

The NHS patient information for semaglutide does not mention smoking cessation as an effect, and the licensed indications have not changed. That is the clinical reality as things stand.

What is still uncertain, and where the research is heading

Prospective trials specifically designed to test semaglutide against nicotine dependence are underway, but results are not yet available in a form that has changed prescribing guidance. Early-phase trials are examining GLP-1 agonists alongside standard cessation pharmacotherapy, but these are small and not yet peer-reviewed at scale.

Several things remain genuinely unclear. First, whether any reduction in craving translates into clinically meaningful quit rates compared with established treatments such as varenicline or nicotine replacement. Second, whether the effect persists after the medicine is stopped or is tied to continued dosing. Third, whether it operates equally across different smoking histories, nicotine dependence levels, or in combination with behavioural support. The semaglutide information page gives a fuller account of the pharmacology involved. For now, the evidence is suggestive but not sufficient to inform a prescribing decision about smoking.

What this means practically: if you smoke, Wegovy may or may not reduce your urge to reach for a cigarette, and you should not start it expecting that it will. Equally, if you are already on Wegovy for weight management and notice reduced cravings, that is worth mentioning to your prescriber, it does not replace dedicated cessation support, but it is a clinically relevant observation. Our page on using Wegovy alongside efforts to stop smoking explores what that conversation with a prescriber might usefully cover.

What this means if you smoke and are considering weight management treatment

Smoking and excess weight frequently coexist, and they compound each other's cardiovascular risk. This matters when a prescriber is assessing suitability for Wegovy, because cardiovascular health is part of the clinical picture. Telling your prescriber you smoke is not a barrier to treatment, it is information the prescriber needs to give you appropriate oversight and aftercare. For a closer look at how these two factors interact clinically, our guide on the relationship between smoking and Wegovy sets out what the current evidence suggests.

Wegovy holds a UK authorisation for reducing major cardiovascular event risk in eligible adults, which is a separate indication from weight management. The Wegovy treatment page covers the weight-management licence in full. The practical takeaway for people who smoke: do not rely on Wegovy as a quit strategy, but do not assume smoking rules you out of weight-management treatment either. A proper clinical assessment resolves both questions at once. If cost is part of your thinking, the Wegovy pricing page sets out what private treatment typically involves in the UK.

For smoking cessation itself, the NHS offers free specialist support through local Stop Smoking Services, and effective licensed medicines exist for that purpose. Combining dedicated cessation support with weight-management treatment, where both are clinically appropriate, is a conversation worth having with a prescriber rather than a choice to make alone. The weight-loss treatment overview covers the broader landscape of what is currently licensed and available.

The clinical bottom line, and what a prescriber actually weighs up

Wegovy is a prescription-only medicine. The decision about whether it is right for you is made by a GPhC-registered Independent Prescriber who reviews your full health picture, not a checklist, not an algorithm. Whether preliminary research on cravings eventually reshapes how GLP-1 medicines are used is a question for future trials and future regulatory decisions. Right now, it does not change the licensed indications, and it does not change the process by which any legitimate UK pharmacy may dispense this medicine.

If you are thinking about weight management treatment and want your prescriber to know you smoke, that context belongs in your consultation. A clinical reviewer who sees the whole picture is better placed to advise you than any headline about GLP-1s and addiction. The frequently asked questions page covers common queries about starting treatment, and the about us page explains the clinical oversight model at nume. If you would like to speak to our prescribers about whether Wegovy is appropriate for you, a free consultation is the right place to start.